Search
ADC Therapeutics SA
ADCTAdd to Watchlist
1.190USD
+0.065+5.70%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
151.33MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.70%
5 Days
+16.67%
1 Month
-9.85%
6 Months
-66.19%
Year to Date
-66.29%
1 Year
-58.25%
Key Figures
1.140Open
1.230High
1.80MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.42%Turnover Ratio
1.140Prev. Close
1.130Low
1.01MTurnover
LossP/E Static
-0.70P/B
0.00%Div Yield TTM
-48.57%ROA
4.98052wk High
1.53Volume Ratio
-157.85MNet Profit
127.17MShares
-0.9762EPS TTM
1.79Beta
-199.54%ROE
2.47052wk Low
8.77%Amplitude
82.66%Gross Margin
151.33MMarket Cap
-3.19Reward/Risk
4.27%Risk Rate
TradingKey Stock Score of ADC Therapeutics SA
Currency: USD Updated: 2026-07-02Key Insights
ADC Therapeutics SA's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 82 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.83.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ADC Therapeutics SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ADC Therapeutics SA Highlights
StrengthsRisks
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.96% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 81.36M.
Fairly Valued
The company’s latest PE is -1.22, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 87.78M shares, decreasing 1.97% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 5.85K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.69.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
1.833
Target Price
+60.82%
Upside Space
ADC Therapeutics SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ADC Therapeutics SA Info
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Ticker SymbolADCT
CompanyADC Therapeutics SA
CEOMallik (Ameet)
Websitehttps://adctherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of ADC Therapeutics SA (ADCT)?
The current price of ADC Therapeutics SA (ADCT) is 1.19.
What is the symbol of ADC Therapeutics SA?
The ticker symbol of ADC Therapeutics SA is ADCT.
What is the 52-week high of ADC Therapeutics SA?
The 52-week high of ADC Therapeutics SA is 4.98.
What is the 52-week low of ADC Therapeutics SA?
The 52-week low of ADC Therapeutics SA is 2.47.
What is the market capitalization of ADC Therapeutics SA?
The market capitalization of ADC Therapeutics SA is 151.33M.
Is ADC Therapeutics SA (ADCT) currently rated as Buy, Hold, or Sell?
According to analysts, ADC Therapeutics SA (ADCT) has an overall rating of Buy, with a price target of 1.83.
What is the Earnings Per Share (EPS TTM) of ADC Therapeutics SA (ADCT)?
The Earnings Per Share (EPS TTM) of ADC Therapeutics SA (ADCT) is -1.12.